SVSusanne J. van Veluw

Susanne J. van Veluw

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susanne J. van Veluw has a total of 209 co-authors. Here are the top co-authors by number of shared publications:

  • Steven M. Greenberg

    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    13 shared publications
  • Steven M Greenberg

    Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA

    10 shared publications
  • Steven Mark Greenberg

    Massachusetts General Hospital

    10 shared publications
  • Matthew P. Frosch

    Department of Neuropathology Massachusetts General Hospital, Harvard Medical School Boston MA USA

    9 shared publications
  • Anand Viswanathan

    J. Philip Kistler Stroke Research Center, Department of Neurology Massachusetts General Hospital, Harvard Medical School Boston MA USA

    7 shared publications
  • Mariel Gailey Kozberg

    J Philip Kistler Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston

    7 shared publications

Latest Publications

  • Open Access

    Neuropathological correlates of MRI-observed hypointense lesions in the APP23 mouse model of cerebral amyloid angiopathy

    by Maarten L van Den Berg, Leon P Munting, Lee Hanlin, Irvin Yi, Joshua Bailey, Douglas S Richardson, Theodore J Zwang, Susanne J van Veluw, Mariel G Kozberg

    Cerebral amyloid angiopathy (CAA) is a small vessel disease associated with hemorrhagic lesions including microbleeds and intracerebral hemorrhage. Growing evidence suggests vascular remodeling may be a critical step leading to CAA-related vessel rupture. The APP23 mouse model is one of few models of cerebral amyloidosis that develop spontaneous microbleeds, visible on T2*-weighted MRI as hypointense lesions. However, it remains unknown whether this model recapitulates the microbleed-associated vascular remodeling observed in human tissue. In this study, we used in-vivo 9.4 T MRI and histopathology to study the neuropathological correlates of MRI-observed hypointense lesions in 18- and 24-month-old APP23 transgenic (Tg) mice and wildtype (WT) littermates (12 Tg, 17 WT). Tg mice had more cortical and deep lesions ( p < 0.001, p < 0.001)). Brains were serially sectioned from a subset of these mice (11 Tg, five WT) and lesions retrieved. All cortical lesions were microbleeds (and in Tg mice). However, 96% of deep lesions (Tg and WT) were calcifications, suggesting caution is needed when interpreting deep hypointense lesions as microbleeds. A qualitative analysis of histopathologically-confirmed microbleeds revealed vascular remodeling including vessel wall thickening and decreased vascular amyloid-β at most vessel rupture sites, resembling human findings, suggesting APP23 mice may be an appropriate model to study mechanisms of CAA-related hemorrhage.

  • Open Access

    In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy

    by Hilde van Den Brink, Mariel G. Kozberg, Nazanin Makkinejad, John E. Kirsch, Michael J. Thrippleton, Thijs W. van Harten, Sabine Voigt, Whitney M. Freeze, Matthias J.P. Van Osch, Anand Viswanathan, et al.

    Blood-brain barrier (BBB) leakage may be an early step in the pathophysiology of cerebral amyloid angiopathy (CAA), possibly preceding hemorrhages. This exploratory study measured BBB leakage in vivo at the level of the leptomeningeal and small parenchymal vessels in patients with probable CAA. We hypothesized that BBB leakage from leptomeningeal and cortical small vessels would be higher in patients with CAA compared with controls and that leakage would be associated with hemorrhagic manifestations of CAA, that is, cortical superficial siderosis (cSS) and lobar cerebral microbleeds (CMBs). Patients with probable CAA without previous intracerebral hemorrhage and non-CAA patients with mild cognitive impairment from the memory clinic were recruited in this prospective observational exploratory study. Participants underwent 3T brain MRI with injection of a gadolinium-based contrast agent (Dotarem). Leakage from leptomeningeal vessels was assessed on postcontrast vs precontrast T2-fluid-attenuated inversion recovery as either focal or sulcal CSF enhancements. Dynamic contrast-enhanced scans were analyzed to quantify permeability-surface area product (PS): a measure of leakage from parenchymal small vessels. Fourteen patients with CAA (mean age 67.7 ± 9.0 years; 57% female) and 7 non-CAA patients with mild cognitive impairment (mean age 70.1 ± 6.5 years; 29% female) were recruited. Focal CSF enhancements were observed similarly often in patients with CAA (7 [50%]) and non-CAA controls (4 [57%], p = 0.98), whereas sulcal CSF enhancements were only seen in patients with CAA (5 [36%] vs 0 [0%]). In patients with CAA, focal and sulcal CSF enhancement counts were associated with higher cSS volume (B = 2.61, p = 0.003; B = 1.02, p = 0.02), but not with CMBs. PS was numerically higher in the cortex in patients with CAA (5.08 ± 4.02 × 10-4 min-1) than in non-CAA controls (1.29 ± 4.08 × 10-4 min-1, p = 0.07), but it was not associated with CMB count or cSS volume (p > 0.67). Leakage of gadolinium-based contrast agent through the BBB can be measured in vivo in CAA from the leptomeningeal vessels, and findings point to likely leakage from cortical small vessels as well. Leakage from leptomeningeal vessels was associated with cSS. Studies with follow-up data need to determine whether these measures could serve as a predictive biomarker in CAA.


  • Top Cited Papers
    Open Access

    Region-specific drivers of CSF mobility measured with MRI in humans

    by Lydiane Hirschler, Bobby A. Runderkamp, Andreas Decker, Thijs W. van Harten, Paul Scheyhing, Philipp Ehses, Léonie Petitclerc, Julia Layer, Eberhard Pracht, Bram F. Coolen, et al.

    Many neurological diseases are characterized by the accumulation of toxic proteins in the brain. This accumulation has been associated with improper clearance from the parenchyma. Recent discoveries highlighted perivascular spaces, which are cerebrospinal fluid (CSF)-filled spaces, as the channels of brain clearance. The forces driving CSF mobility within perivascular spaces are still debated. Here we present a noninvasive, CSF-specific magnetic resonance imaging technique (CSF-Selective T 2 -prepared REadout with Acceleration and Mobility-encoding) that enables detailed in vivo measurement of CSF mobility in humans, down to the level of perivascular spaces located around penetrating vessels, which is close to protein production sites. We find region-specific drivers of CSF mobility and demonstrate that CSF mobility can be increased by entraining vasomotion. Furthermore, we find region-specific CSF mobility alterations in patients with cerebral amyloid angiopathy, a brain disorder associated with clearance impairment. The availability of this technique opens up avenues to investigate the impact of CSF-mediated clearance in neurodegeneration and sleep.


  • CAA-related enlarged perivascular spaces are associated with abnormal angioarchitecture in human brain tissue: A key role for white matter atrophy?

    by Marion Giraud, Dae Hee Yun, Leon P Munting, Kwanghun Chung, Brian J Bacskai, Steven M Greenberg, Matthew P Frosch, Alain Goriely, Susanne J van Veluw, Sylvie Lorthois

    Cerebral Amyloid Angiopathy, a common age-related small vessel disease leading to hemorrhagic stroke, shares many characteristics with Alzheimer’s disease: toxic amyloid deposits, microvascular alterations and enlarged perivascular spaces (EPVS). Together, PVS enlargement, reduced amyloid-β clearance and further accumulation form a vicious cycle underlying disease progression. Yet, the neuropathological correlates of EPVS, including the associated angioarchitecture, are poorly understood. We provide quantitative 3D reconstructions of human brain microvascular networks and their topographical associations with EPVS in large volumes of cleared human tissue spanning over the gray/white matter interface. We reveal the existence of six vessel/PVS morphotypes, including sinusoid and helical vessels, enclosed in increasingly enlarged PVS, and increasingly disconnected from their surrounding network. Based on the buckling of elongated structures, we discuss how they likely result from generic processes of mechanical origin, driven by white matter atrophy, thus advancing our understanding of the pathophysiological overlap between amyloid-related and cerebrovascular disease.


  • Open Access

    Vasomotion loss precedes impaired cerebrovascular reactivity and microbleeds in cerebral amyloid angiopathy

    by Mariel G Kozberg, Leon P Munting, Lee H Hanlin, Corinne A Auger, Maarten L van Den Berg, Baudouin Denis de Senneville, Lydiane Hirschler, Jan M Warnking, Emmanuel L Barbier, Christian T Farrar, et al.

    Cerebral amyloid angiopathy (CAA) is a cerebral small vessel disease in which amyloid-β accumulates in vessel walls. CAA is a leading cause of symptomatic lobar intracerebral haemorrhage and an important contributor to age-related cognitive decline. Recent work has suggested that vascular dysfunction may precede symptomatic stages of CAA, and that spontaneous slow oscillations in arteriolar diameter (termed vasomotion), important for amyloid-β clearance, may be impaired in CAA. To systematically study the progression of vascular dysfunction in CAA, we used the APP23 mouse model of amyloidosis, which is known to develop spontaneous cerebral microbleeds mimicking human CAA. Using in vivo 2-photon microscopy, we longitudinally imaged unanesthetized APP23 transgenic mice and wildtype (WT) littermates from 7 to 14 months of age, tracking amyloid-β accumulation and vasomotion in individual pial arterioles over time. MRI was used in separate groups of 12-, 18- and 24-month-old APP23 transgenic mice and WT littermates to detect microbleeds and to assess cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) with pseudo-continuous arterial spin labelling. We observed a significant decline in vasomotion with age in APP23 mice, while vasomotion remained unchanged in WT mice with age. This decline corresponded in timing to initial vascular amyloid-β deposition (∼8–10 months of age), although it was more strongly correlated with age than with vascular amyloid-β burden in individual arterioles. Declines in vasomotion preceded the development of MRI-visible microbleeds and the loss of smooth muscle actin in arterioles, both of which were observed in the majority of APP23 mice by 18 months of age. Additionally, CBF and evoked CVR were intact in APP23 mice at 12 months of age, but significantly lower in APP23 mice by 24 months of age. Our findings suggest that a decline in spontaneous vasomotion is an early, potentially pre-symptomatic, manifestation of CAA and vascular dysfunction, and a possible future treatment target.


  • Top Cited Papers
    Open Access

    Sex differences in age-associated neurological diseases—A roadmap for reliable and high-yield research

    by Anna K. Bonkhoff, Gillian Coughlan, Valentina Perosa, Kenda Alhadid, Markus D. Schirmer, Robert W. Regenhardt, Susanne van Veluw, Rachel Buckley, Michael D. Fox, Natalia S. Rost

    Once taken into consideration, sex differences in neurological diseases emerge in abundance: (i) Stroke severity is significantly higher in females than in males, (ii) Alzheimer’s disease (AD) pathology is more pronounced in females, and (iii) conspicuous links with hormonal cycles led to female-specific diagnoses, such as catamenial migraines and epilepsy. While these differences receive increasing attention in isolation, they likely link to similar processes in the brain. Hence, this review aims to present an overview of the influences of sex chromosomes, hormones, and aging on male and female brains across health and disease, with a particular focus on AD and stroke. The focus here on advancements across several fields holds promise to fuel future research and to lead to an enriched understanding of the brain and more effective personalized neurologic care for all.


  • Open Access

    Cerebrospinal Fluid Beta‐Amyloid Concentration and Clinical and Radiographic Manifestations of Cerebral Amyloid Angiopathy

    by Baris Alten, Elif Gokcal, Andrew Warren, Susanne J. van Veluw, Mariel Kozberg, M. Edip Gurol, Anand Viswanathan, Steven M. Greenberg

    Background: Cerebral amyloid angiopathy (CAA) is driven by vascular Aβ (amyloid‐beta) deposition, which can be detected as reduced Aβ species in cerebrospinal fluid (CSF). We sought to identify relationships between CSF Aβ and tau concentrations and various manifestations of CAA. Methods: This is a retrospective cross‐sectional single‐center study of patients diagnosed with CAA per Boston Criteria version 2.0, had magnetic resonance imaging brain scans, and underwent CSF testing for Aβ and tau concentrations between 2008 and 2022. Associations between clinical/magnetic resonance imaging features and CSF biomarker concentrations were investigated with univariate and multivariate models. Results: We identified 31 patients aged 69.6±8.4 years, of whom 20 presented with cognitive complaints, 9 with CAA‐related macrohemorrhage (lobar intraparenchymal or convexity subarachnoid hemorrhage), and 2 with transient focal neurological episodes. Presence of macrohemorrhage (301.8±112 pg/mL versus 400.9±123 pg/mL, P =0.029), cortical superficial siderosis (309.6±131 mg/dL versus 412.3±100 pg/mL, P =0.021), and severe enlarged perivascular spaces in centrum semiovale (285.8±91 pg/mL versus 428.3±117 pg/mL, P P =0.03) and trended toward having higher p‐tau (phosphorylated tau at threonine 181) concentrations (75.69±39 pg/mL versus 49.24±22 pg/mL, P =0.05). Conclusions: Lower CSF Aβ42, suggesting higher amyloid burden, is associated with CAA‐related macrohemorrhages and severe enlarged perivascular spaces in centrum semiovale, suggesting potential mechanistic links and CSF Aβ42 as a potential biomarker for progression of CAA. CSF tau concentrations are linked to cognitive complaints, likely representing comorbid Alzheimer disease pathology.


  • Top Cited Papers

    Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms

    by Steven M. Greenberg, Francesco Bax, Susanne J. van Veluw

    Three monoclonal antibodies directed against specific forms of the amyloid-β (Aβ) peptide have been granted accelerated or traditional approval by the FDA as treatments for Alzheimer disease, representing the first step towards bringing disease-modifying treatments for this disease into clinical practice. Here, we review the detection, underlying pathophysiological mechanisms and clinical implications of amyloid-related imaging abnormalities (ARIA), the most impactful adverse effect of anti-Aβ immunotherapy. ARIA appears as regions of oedema or effusions (ARIA-E) in brain parenchyma or sulci or as haemorrhagic lesions (ARIA-H) in the form of cerebral microbleeds, convexity subarachnoid haemorrhage, cortical superficial siderosis or intracerebral haemorrhage. Analysis of the radiographic appearance of ARIA, its clinical risk factors and underlying neuropathology, and results from animal models point to a central role for cerebral amyloid angiopathy — a condition characterized by cerebrovascular Aβ deposits — as a key component, either as a direct target for antibody-mediated inflammation or as recipient of Aβ mobilized from plaques in the Alzheimer brain parenchyma. The great majority of ARIA occurrences are associated with mild or no clinical symptoms. However, ~5% of all ARIA events are severe enough to result in hospitalization, permanent disability or death and thus raise challenging clinical questions regarding patient selection and use of concomitant agents. Therefore, identifying novel approaches to predicting, modelling, preventing and treating ARIA remains a key step towards allowing safe use of anti-Aβ immunotherapy for the world’s rapidly ageing population.


  • Genetics of intracerebral hemorrhage

    by Tamara N Kimball, Reinier Wp Tack, Anna Chen, Savvina Prapiadou, Jasper R Senff, Benjamin Yq Tan, Sanjula D Singh, Susanne J van Veluw, Steven M Greenberg, Jonathan Rosand, et al.

    Spontaneous intracerebral hemorrhage(ICH) represents a life-threatening form of stroke, marked by its impact on survival and quality of life. ICH can be categorized from monogenic disorders linked to causal germline variants in ICH-related genes to complex sporadic cases, highlighting the interaction among lifestyle factors, environmental influences, and genetic components in determining risk. Among sporadic ICH, the influence of these factors varies across ICH subtypes, evidenced by heritability rates of up to 73% for lobar ICH versus 34% for non-lobar ICH. This review presents an outline of the genetic landscape of ICH, covering both monogenic and sporadic forms. It highlights associations between ICH risk and genetic variants, including rare and common variants in genes such as COL4A1, COL4A2, APOE, ACE, MTHFR, and PMF1 . However, replication has been constrained, and most findings originate from single-candidate gene studies, largely due to ancestry heterogeneity, small sample sizes, and scarce subtype-specific data. To bridge this gap, collaborative efforts like the International Stroke Genetic Consortium have been established. Additionally, the review discusses the emerging role of polygenic risk scores, Mendelian randomization, and the potential of genetic and omics research to elucidate causal pathobiology. Such insights could lead to preventive measures and personalized ICH treatment strategies.


  • Open Access

    Neuropathological Correlates of White Matter Hyperintensities in Cerebral Amyloid Angiopathy

    by Nazanin Makkinejad, Maria Clara Zanon Zotin, Hilde van Den Brink, Corinne A. Auger, Kali A. Vom Eigen, Juan Eugenio Iglesias, Steven M. Greenberg, Valentina Perosa, Susanne J. van Veluw

    Background: White matter hyperintensities (WMHs) are frequently observed on magnetic resonance imaging (MRI) in patients with cerebral amyloid angiopathy (CAA). The neuropathological substrates that underlie WMHs in CAA are unclear, and it remains largely unexplored whether the different WMH distribution patterns associated with CAA (posterior confluent and subcortical multispot) reflect alternative pathophysiological mechanisms. Methods and Results: We performed a combined in vivo MRI—ex vivo MRI—neuropathological study in patients with definite CAA. Formalin‐fixed hemispheres from 19 patients with CAA, most of whom also had in vivo MRI available, underwent 3T MRI, followed by standard neuropathological examination of the hemispheres and targeted neuropathological assessment of WMH patterns. Ex vivo WMH volume was independently associated with CAA severity ( P =0.046) but not with arteriolosclerosis ( P =0.743). In targeted neuropathological examination, compared with normal‐appearing white matter, posterior confluent WMHs were associated with activated microglia ( P =0.043) and clasmatodendrosis ( P =0.031), a form of astrocytic injury. Trends were found for an association with white matter rarefaction ( P =0.074) and arteriolosclerosis ( P =0.094). An exploratory descriptive analysis suggested that the histopathological correlates of WMH multispots were similar to those underlying posterior confluent WMHs. Conclusions: This study confirmed that vascular amyloid β severity in the cortex is significantly associated with WMH volume in patients with definite CAA. The histopathological substrates of both posterior confluent and WMH multispots were comparable, suggesting overlapping pathophysiological mechanisms, although these exploratory observations require confirmation in larger studies.